SHENZHEN, China, Aug. 8, 2021 /PRNewswire/ -- ImmVira announces MVR-C5252 targeting Glioblastoma has received the U.S. FDA clearance to proceed with clinical trial on August 6, 2021.

SHENZHEN, China, Aug. 6, 2021 /PRNewswire/ -- ImmVira announced that as a global first, its lead oncolytic virus therapy program MVR-T3011 IV (also known as T3011), obtained approval from National Medical Products Administration ("NMPA") for clinical trial for treatments using intravenous administration (IV) on August 6, 2021.

SHENZHEN, China, June 11, 2021 /PRNewswire/ -- ImmVira announced that in the Phase II Clinical Trials of its leading oncolytic virus product, MVR-T3011* as intratumoral administration (MVR-T3011 IT), ImmVira has completed the first dosing in both China and the U.S. on May 28 2021 and June 11 2021, respectively.

SHENZHEN, China, June 2, 2021 /PRNewswire/ -- ImmVira will present results from its clinical Phase I study of MVR-T3011 via intratumoral (IT) administration at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting on June 4-8, 2021 for the first time.

SHENZHEN, China, April 19, 2021 /PRNewswire/ -- On April 15, 2021, ImmVira presents the preclinical study results of MVR-T3011 via intravenous administration through publication in a virtual poster at the AACR annual meeting. MVR-T3011 is a replication competent and genetically modified oncolytic herpes simplex virus-1 expressing human interleukin-12 and anti-PD-1 antibody. ImmVira owns the global right for development and commercialization of MVR-T3011 via intravenous administration.

SHENZHEN, China, Dec. 31, 2020 /PRNewswire/ -- ImmVira Group Company ("the Company"), a biotechnology platform dedicated to the development of oncolytic virus("OV") and vector type approaches to create more effective and safer therapies against cancer, announced today the signing of Series C financing.